Page last updated: 2024-09-05

erlotinib hydrochloride and iohexol

erlotinib hydrochloride has been researched along with iohexol in 2 studies

Compound Research Comparison

Studies
(erlotinib hydrochloride)
Trials
(erlotinib hydrochloride)
Recent Studies (post-2010)
(erlotinib hydrochloride)
Studies
(iohexol)
Trials
(iohexol)
Recent Studies (post-2010) (iohexol)
4,3537863,0335,1967441,760

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
de Ruysscher, D; Dingemans, AM; Lind, JS; Meijerink, MR; Ollers, MC; Postmus, PE; Smit, EF; van Kuijk, C1
DiPiro, PJ; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M1

Trials

2 trial(s) available for erlotinib hydrochloride and iohexol

ArticleYear
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
    European radiology, 2010, Volume: 20, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Contrast Media; Erlotinib Hydrochloride; Female; Humans; Iohexol; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Radiographic Image Enhancement; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2010
Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy.
    Clinical radiology, 2014, Volume: 69, Issue:8

    Topics: Carcinoma, Non-Small-Cell Lung; Contrast Media; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Iohexol; Lung Neoplasms; Male; Multidetector Computed Tomography; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiographic Image Enhancement; Reproducibility of Results; Treatment Outcome; Tumor Burden

2014